Search Results
Mar 31, 2026, 08:28 ET NYU Langone Transplant Institute Celebrates 10 Years of Saving Lives
first gene-edited pig-to-human kidney transplant (2021) and the first
More news about: NYU Langone Health
Mar 31, 2026, 08:00 ET Kalohexis Appoints Tony Mitchell as Chief Financial Officer
where he led the accounting and finance functions, including IPO readiness. Previously, Mr. Mitchell served as VP, Controller at Jaguar Gene Therapy, a clinical-stage gene therapy company, where he oversaw the build out of the accounting function. Prior, Mr. Mitchell served in leadership roles responsible
More news about: Kalohexis
Mar 31, 2026, 07:00 ET FormativGroup Acquires Flok to Expand Salesforce Service and Experience Cloud Expertise
advanced solution capabilities. Together we continue to build an integrated and scalable platform designed to accelerate innovation in our markets," said Gene Chao, CEO of FormativGroup."Flok was established to focus on providing our clients with very strong application solution capabilities with methodologies
More news about: Rockbridge Growth Equity; FormativGroup
Mar 31, 2026, 04:00 ET Gentronix Now Operating Under the Scantox Brand
Scantox has invested significantly in expanding its genetic toxicology and genomic safety capabilities. The team has scaled Big Blue® transgenic rodent gene mutation assay capacity to meet rising market demand, developed an Enhanced Ames Test program, and most recently acquired the DuplexSeq™ nonclinical
More news about: Scantox Group
Mar 31, 2026, 02:10 ET Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children
Research has shown that the pathogenesis of ACH is driven by aberrant activation of the fibroblast Growth Factor Receptor 3 (FGFR3) caused by FGFR3 gene mutations, which suppress normal endochondral ossification [1]. Targeted inhibitors offer the potential to
More news about: Abbisko Therapeutics Co., Ltd.
Mar 30, 2026, 15:52 ET QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Mar 30, 2026, 13:00 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 30, 2026, 10:25 ET EMA Aesthetics Unveils BLŪPRIN™ at AMWC Monaco, Introducing a New Standard in Regenerative Exosomes
cord blood-derived exosomes demonstrated:Significantly stronger results at lower concentrationsBroad modulation of gene expression, including engagement of pathways associated with normal cellular function and repairConsistent, controlled resultsThis
More news about: EMA Aesthetics
Mar 30, 2026, 08:58 ET Jeffrey Modell Foundation to Host NIH Immunology Leader for World Primary Immunodeficiency Week
research focuses on immune deficiency and immune dysregulation, STAT transcription factor signaling defects in natural killer cells as well as novel gene discovery and therapeutic modulation in immune mediated disease. She has dedicated her academic career to translational research and clinical care of
More news about: Jeffrey Modell Foundation
Mar 30, 2026, 07:00 ET Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration
(MHLW) granted both Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations for IRDs to MCO-010—marking the first time a retinal gene therapy has received such broad IRD designations in the country. These designations provide a clear accelerated regulatory pathway, including prioritized
More news about: Nanoscope Therapeutics
Mar 30, 2026, 04:18 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 29, 2026, 08:07 ET RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Mar 27, 2026, 10:01 ET Human Identification Market worth $1.69 billion by 2031 | MarketsandMarkets™
(UK), Bode Cellmark Forensics Inc. (US), Carolina Biological Supply (US), Genetek Biopharma GmbH (Germany), STRmix Limited (New Zealand), Ningbo HEALTH Gene Technologies Co., Ltd. (China), and SoftGenetics (US).Browse Adjacent Markets:
More news about: MarketsandMarkets
Mar 27, 2026, 09:35 ET NatGold Digital's Appointment of ECM Capital Advisors Expands Its Global Development Network for Qualifying Gold Resources
qualifying gold resources is a top priority. Gene and his team are exceptionally well positioned to help us build that pipeline and connect with the global mining community at the highest levels."ECM Capital Advisors was founded by Eugene ("Gene") McBurney, one of the most experienced and widely
More news about: NatGold Digital Ltd.
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
active clinical candidates globally. To keep up with this massive demand, the FDA just stepped in with new flexibility measures for cell and gene therapies[2]. By easing manufacturing requirements from the lab to commercial launch, regulators are accelerating the timeline for life-saving
More news about: USA News Group
Mar 27, 2026, 09:05 ET Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
regarding Castle's posters and its participation at AAD, please visit booth #3345.About DecisionDx-MelanomaDecisionDx-Melanoma is a gene expression profile (GEP) test designed to analyze tumor biology to deliver a personalized risk assessment for patients with stage I–III cutaneous melanoma,
More news about: Castle Biosciences, Inc.
Mar 27, 2026, 09:00 ET Cineverse to Launch New Streaming Channel Featuring Jay Mohr and WITZ Podcast Network's Mohr Stories
Include Ron Funches, Jay Leno, Joe Mantegna, Patton Oswalt, Kevin Pollak, Andy Richter, George Wallace, Flavor Flav, Michael Eric Dyson, Seth Rollins, Gene Simmons, Billy Gibbons, Byron Scott, and Jeanie Buss
More news about: Cineverse Corp.
Mar 26, 2026, 16:38 ET BioMarin apresenta novos dados sobre o impacto positivo do tratamento precoce com VOXZOGO® (vosoritida) na proporcionalidade e envergadura dos braços em crianças com acondroplasia na Reunião Anual de Genética Clínica de 2026 do Colégio Americano de Genética Médica e Genômica (ACMG)
ossificação endocondral, causando baixa estatura e alterações na arquitetura dos ossos longos, coluna, face e base do crânio. É causada por uma alteração no gene FGFR3, regulador negativo do crescimento ósseo.Mais de 80% das crianças com acondroplasia têm pais de estatura média e apresentam a condição
More news about: BioMarin
Mar 26, 2026, 16:37 ET QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Mar 26, 2026, 14:17 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
development of advanced therapies for highly individualized conditions. Rapid advances in technologies such as antisense oligonucleotides, genome editing, gene therapies, and RNA-based treatments are making it possible to design precisely targeted interventions for very small patient populations, even individual
More news about: Critical Path Institute
Mar 26, 2026, 14:01 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
development of advanced therapies for highly individualized conditions. Rapid advances in technologies such as antisense oligonucleotides, genome editing, gene therapies, and RNA-based treatments are making it possible to design precisely targeted interventions for very small patient populations, even individual
More news about: Critical Path Institute
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Mar 26, 2026, 10:00 ET High Throughput Screening Market to Reach USD 17,880 Million by 2031, Driven by Drug Discovery Advancements | Valuates Reports
institutions and contract research providers are expanding access to advanced assay capabilities and specialized screening expertise. Rising biologics, gene therapy, and cell therapy development programs are further strengthening demand for scalable and reproducible screening infrastructures. Continuous
More news about: Valuates Reports
Mar 26, 2026, 09:05 ET Made Scientific and New Jersey Institute of Technology Announce Partnership to Enhance Graduate-Level Cell and Gene Therapy Bioprocessing Curriculum
Collaboration Leverages Made Scientific's Industry Expertise and Workforce Development Initiative to Empower the Next Generation of Cell and Gene Therapy ProfessionalsPRINCETON, N.J. and NEWARK, N.J., March 26, 2026
More news about: Made Scientific, Inc.